Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: <scp>TALAPRO</scp> ‐2 Japanese Subgroup Analysis

Authors

Hiroaki Kikukawa
Nobuaki Matsubara (ORCID: https://orcid.org/0000-0002-9203-4245)
Natsuki Hori
Yuko Mori (ORCID: https://orcid.org/0000-0003-1919-2463)
Atsushi Komaru (ORCID: https://orcid.org/0000-0002-6350-3436)
Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
Shigeyuki Toyoizumi (ORCID: https://orcid.org/0000-0002-7011-5263)
Hirotsugu Uemura (ORCID: https://orcid.org/0000-0002-3665-9523)
Kazuo Nishimura (ORCID: https://orcid.org/0000-0002-7644-1350)
Yoshiko Umeyama (ORCID: https://orcid.org/0000-0003-4967-0382)
Hiroji Uemura (ORCID: https://orcid.org/0000-0001-7943-1564)
Motonobu Nakamura (ORCID: https://orcid.org/0000-0003-3038-1361)
Takeo Kosaka (ORCID: https://orcid.org/0000-0002-4371-4594)
Kazuki Kobayashi (ORCID: https://orcid.org/0000-0002-9365-9490)
Hideaki Miyake

Institutions

Yokohama City University Medical Center (JP)
Hamamatsu University School of Medicine (JP)
National Hospital Organization Kyushu Cancer Center (JP)
Kindai University Hospital (JP)
Kanazawa University Hospital (JP)
Keio University Hospital (JP)
Chiba Cancer Center (JP)
National Cancer Center Hospital East (JP)
Yokosuka Kyosai Hospital (JP)
Pfizer (Japan) (JP)
Osaka International Cancer Institute (JP)
Kumamoto Medical Center (JP)
Kobe University (JP)
Yokohama City University (JP)

Publication Details

Journal: Cancer Medicine
Published: 2024-12-31
DOI: https://doi.org/10.1002/cam4.70333
Citations: 1
Primary Topic: PARP inhibition in cancer therapy
Type: article
Field-Weighted Citation Impact: 0.28

Funders

Pfizer
Astellas Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO ‐2 Japanese Subgroup Analysis

Hiroaki Kikukawa, Nobuaki Matsubara, Natsuki Hori, Yuko Mori et al.

Dec 31, 2024

1 citations

Cancer Medicine

PARP inhibition in cancer therapy

0.28

article

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO ‐2 Japanese Subgroup Analysis

Hiroaki Kikukawa, Nobuaki Matsubara, Natsuki Hori, Yuko Mori, Atsushi Komaru, Atsushi Mizokami, Shigeyuki Toyoizumi, Hirotsugu Uemura, Kazuo Nishimura, Yoshiko Umeyama, Hiroji Uemura, Motonobu Nakamura, Takeo Kosaka, Kazuki Kobayashi, Hideaki Miyake

December 31, 2024article en

1 citations

Abstract

No abstract available for this paper.

Cancer MedicineVol. 14(1)

Yokohama City University Medical Center (JP), Hamamatsu University School of Medicine (JP), National Hospital Organization Kyushu Cancer Center (JP), Kindai University Hospital (JP), Kanazawa University Hospital (JP), Keio University Hospital (JP), Chiba Cancer Center (JP), National Cancer Center Hospital East (JP), Yokosuka Kyosai Hospital (JP), Pfizer (Japan) (JP), Osaka International Cancer Institute (JP), Kumamoto Medical Center (JP), Kobe University (JP), Yokohama City University (JP)

Pfizer, Astellas Pharma

Openalex Percentile: Top 32%

PARP inhibition in cancer therapy

0.28

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.